Cargando…

Salvage surgery for cervical radioiodine refractory (18)F-FDG-PET positive recurrence of papillary thyroid cancer

PURPOSE: Five percent of patients with differentiated thyroid cancer are diagnosed with radioiodine refractory relapse in the course of the disease. For isolated or oligometastatic cervical recurrence, resection or another local treatment is recommended. In this study, the impact of surgical treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiapponi, C, Alakus, H, Faust, M, Schultheis, A M, Rosenbrock, J, Schmidt, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494412/ https://www.ncbi.nlm.nih.gov/pubmed/34424854 http://dx.doi.org/10.1530/EC-21-0232

Ejemplares similares

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment
por: Chiapponi, Costanza, et al.
Publicado: (2023)

Lymphatic Vessel Invasion in Routine Pathology Reports of Papillary Thyroid Cancer
por: Chiapponi, Costanza, et al.
Publicado: (2022)

(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib
por: Ahmaddy, Freba, et al.
Publicado: (2021)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Tenosynovial Giant Cell Tumor of Foot in a Patient with Radioiodine-Refractory Thyroid Cancer: Imaging Findings on FDG-PET/CT, MRI, and Radioiodine Scan
por: Loharkar, Sarvesh, et al.
Publicado: (2022)

Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis
por: Hescheler, Daniel A., et al.
Publicado: (2021)

2-[(18)F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study
por: Gay, Stefano, et al.
Publicado: (2022)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
por: Qiu, Xian, et al.
Publicado: (2022)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
por: Li, Genpeng, et al.
Publicado: (2022)

Usefulness of PET/CT with (18)F-FDG in Patients with Differentiated Thyroid Carcinoma after Radioiodine Therapy: An Italian Multicenter Study
por: Filippi, Luca, et al.
Publicado: (2021)

The role of 18F-FDG PET/CT testing in the management of a papillary thyroid carcinoma
por: Florczak, Agnieszka, et al.
Publicado: (2013)

Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT
por: Hitu, Liviu, et al.
Publicado: (2020)

Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study
por: Liu, Hanqing, et al.
Publicado: (2023)

Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
por: Chiapponi, Costanza, et al.
Publicado: (2022)

Findings of I-131 SPECT/CT, (18)F-FDG, and (68)Ga-FAPI-04 PET/CT Imaging in a Patient Treated with Radioiodine Therapy for Metastatic Papillary Thyroid Carcinoma
por: Tatar, Gamze, et al.
Publicado: (2023)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
por: Jin, Yuchen, et al.
Publicado: (2017)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review
por: Wong, Kai-Pun, et al.
Publicado: (2012)

Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
por: Takeuchi, Satoshi, et al.
Publicado: (2023)

Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?
por: Krčálová, Eva, et al.
Publicado: (2016)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on (18)F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma
por: Jung, Ji-hoon, et al.
Publicado: (2015)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
por: Yoon, Seokho, et al.
Publicado: (2015)

Adrenocortical Oncocytic Carcinoma and Papillary Thyroid Carcinoma Incidentally Detected in an Asymptomatic Patient by F-18 FDG PET/CT
por: Al Balooshi, Batool, et al.
Publicado: (2018)

Characteristics of thyroid incidentalomas detected by pre-treatment [(18)F]FDG PET or PET/CT in patients with cervical cancer
por: Lee, Won-Moo, et al.
Publicado: (2012)

Clinical role of (18)F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer
por: Tang, Xiaowei, et al.
Publicado: (2023)

Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer—To Treat or Not to Treat
por: van Velsen, Evert F S, et al.
Publicado: (2023)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

F-18 FDG-PET-CT in the Diagnostic of a Late Medullary Thyroid Carcinoma Recurrence in a Patient with Follicular-Papillary Thyroid Cancer
por: Piciu, Doina, et al.
Publicado: (2014)

(18)F-FDG PET/CT-Guided Clinical Management of the Rare Aggressive "Columnar-Cell" Variant of Papillary Thyroid Cancer
por: Vadrucci, Manuela, et al.
Publicado: (2016)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation
por: Anekpuritanang, Tauangtham, et al.
Publicado: (2021)

Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers
por: Roy, Malanie, et al.
Publicado: (2022)

Black thyroid: a note for the surgeon, the pathologist and the dermatologist
por: Chiapponi, Costanza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_15h5q4oldua8eoivj4pjeidq59